168 related articles for article (PubMed ID: 8363372)
1. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Walzer PD; Foy J; Steele P; White M
Antimicrob Agents Chemother; 1993 Jul; 37(7):1436-43. PubMed ID: 8363372
[TBL] [Abstract][Full Text] [Related]
2. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.
Walzer PD; Foy J; Steele P; Kim CK; White M; Klein RS; Otter BA; Allegra C
Antimicrob Agents Chemother; 1992 Sep; 36(9):1935-42. PubMed ID: 1416884
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.
Walzer PD; Kim CK; Foy JM; Linke MJ; Cushion MT
Antimicrob Agents Chemother; 1988 Jan; 32(1):96-103. PubMed ID: 3258144
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
Cirioni O; Giacometti A; Scalise G
J Antimicrob Chemother; 1997 Jan; 39(1):45-51. PubMed ID: 9044027
[TBL] [Abstract][Full Text] [Related]
6. Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model.
Brun-Pascaud M; Chau F; Derouin F; Girard PM
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():57-62. PubMed ID: 9579714
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Ma L; Borio L; Masur H; Kovacs JA
J Infect Dis; 1999 Dec; 180(6):1969-78. PubMed ID: 10558954
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
Hughes WT
Antimicrob Agents Chemother; 1988 May; 32(5):623-5. PubMed ID: 3260765
[TBL] [Abstract][Full Text] [Related]
9. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Brun-Pascaud M; Chau F; Garry L; Jacobus D; Derouin F; Girard PM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2067-70. PubMed ID: 8878582
[TBL] [Abstract][Full Text] [Related]
10. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
Chang HR; Arsenijevic D; Comte R; Polak A; Then RL; Pechère JC
Antimicrob Agents Chemother; 1994 Aug; 38(8):1803-7. PubMed ID: 7986011
[TBL] [Abstract][Full Text] [Related]
11. Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.
Walzer PD; Runck J; Orr S; Foy J; Steele P; White M
Antimicrob Agents Chemother; 1997 Feb; 41(2):242-50. PubMed ID: 9021174
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.
Locher HH; Schlunegger H; Hartman PG; Angehrn P; Then RL
Antimicrob Agents Chemother; 1996 Jun; 40(6):1376-81. PubMed ID: 8726004
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic failure of trimethoprim/sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.
al-Tawfiq JA; Sorensen SJ; Cushing HE
Ann Pharmacother; 1999 Apr; 33(4):413-5. PubMed ID: 10332530
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Bucher HC; Griffith L; Guyatt GH; Opravil M
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
[TBL] [Abstract][Full Text] [Related]
15. Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS.
Slavik RS; Rybak MJ; Lerner SA
Ann Pharmacother; 1998 Feb; 32(2):189-92. PubMed ID: 9496403
[TBL] [Abstract][Full Text] [Related]
16. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
Podzamczer D; Santín M; Jimenez J; Casanova A; Bolao F; Gudiol GR
AIDS; 1993 Apr; 7(4):501-6. PubMed ID: 8507417
[TBL] [Abstract][Full Text] [Related]
17. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
18. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Korraa H; Saadeh C
South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
[TBL] [Abstract][Full Text] [Related]
19. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
Fisher RG; Nageswaran S; Valentine ME; McKinney RE
AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
[TBL] [Abstract][Full Text] [Related]
20. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
